Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,403 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination of disease duration-to-age at diagnosis and hemoglobin A1c-to-serum C-peptide reactivity ratios predicts patient response to glucose-lowering medication in type 2 diabetes: A retrospective cohort study across Japan (JDDM59).
Kanatsuka A, Sato Y, Higashi Y, Goto Y, Kawai K, Maegawa H; Japan Diabetes Data Management Study Group (JDDM). Kanatsuka A, et al. Among authors: sato y. J Diabetes Investig. 2021 Nov;12(11):1967-1977. doi: 10.1111/jdi.13558. Epub 2021 May 12. J Diabetes Investig. 2021. PMID: 33837666 Free PMC article.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
Kobayashi K, Yokoh H, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K; SUCCESS Study Group. Kobayashi K, et al. Among authors: sato y. Diabetes Obes Metab. 2014 Aug;16(8):761-5. doi: 10.1111/dom.12264. Epub 2014 Feb 18. Diabetes Obes Metab. 2014. PMID: 24447683 Clinical Trial.
Evaluation of insulin regimens as an effective option for glycemic control in patients with type 2 diabetes: A propensity score-matched cohort study across Japan (JDDM31).
Kanatsuka A, Sato Y, Kawai K, Hirao K, Kobayashi M, Kashiwagi A; Japan Diabetes Clinical Data Management Study Group. Kanatsuka A, et al. Among authors: sato y. J Diabetes Investig. 2014 Sep;5(5):539-47. doi: 10.1111/jdi.12194. Epub 2014 Feb 26. J Diabetes Investig. 2014. PMID: 25411622 Free PMC article.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial.
Yokoh H, Kobayashi K, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K. Yokoh H, et al. Among authors: sato y. J Diabetes Investig. 2015 Mar;6(2):182-91. doi: 10.1111/jdi.12282. Epub 2014 Sep 24. J Diabetes Investig. 2015. PMID: 25802726 Free PMC article.
Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38).
Kanatsuka A, Sato Y, Kawai K, Hirao K, Kobayashi M, Kashiwagi A; Japan Diabetes Clinical Data Management Study Group (JDDM); Abe N, Arai K, Fujiya H, Fukumoto Y, Dake F, Iizumi T, Ito M, Iwasaki K, Kanamori A, Kato S, Kato M, Kawara A, Kimura K, Chikamori K, Iemitsu K, Kou S, Kudo M, Kurihara Y, Lee G, Tsuruoka A, Manda N, Matoba K, Hayashi H, Minami M, Kuribayashi N, Miyazawa K, Chiba Y, Osonoi T, Nakamura S, Sasaki H, Komori K, Oishi M, Okada A, Okuguchi F, Yanagisawa M, Sugimoto H, Sugiyama H, Takai M, Takaki M, Takamura H, Takeda H, Takeda H, Tanaka K, Miwa T, Tomonaga O, Taguchi M, Yamazaki K, Wada T, Yagi N, Yamaoka K, Yuhara A. Kanatsuka A, et al. Among authors: sato y. J Diabetes Investig. 2016 May;7(3):386-95. doi: 10.1111/jdi.12430. Epub 2015 Nov 12. J Diabetes Investig. 2016. PMID: 27330726 Free PMC article.
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study).
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K; PRIME-V Study Group. Koshizaka M, et al. Among authors: sato y. Diabetes Obes Metab. 2019 Aug;21(8):1990-1995. doi: 10.1111/dom.13750. Epub 2019 May 8. Diabetes Obes Metab. 2019. PMID: 30993861 Free PMC article. Clinical Trial.
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K; PRIME-V study group. Koshizaka M, et al. Among authors: sato y. J Diabetes Investig. 2021 Feb;12(2):200-206. doi: 10.1111/jdi.13340. Epub 2020 Aug 20. J Diabetes Investig. 2021. PMID: 32623839 Free PMC article. Clinical Trial.
14,403 results
You have reached the last available page of results. Please see the User Guide for more information.